Sihuan Pharmaceutical Holdings Group Past Earnings Performance

Past criteria checks 0/6

Sihuan Pharmaceutical Holdings Group's earnings have been declining at an average annual rate of -11.1%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been declining at an average rate of 7.8% per year.

Key information

-11.1%

Earnings growth rate

-11.5%

EPS growth rate

Pharmaceuticals Industry Growth	7.3%
Revenue growth rate	-7.8%
Return on equity	-5.0%
Net Margin	-2.9%
Last Earnings Update	31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Sihuan Pharmaceutical Holdings Group makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:TEL1 Revenue, expenses and earnings (CNY Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	1,861	-54	911	578
30 Jun 23	1,773	-2,041	898	773
31 Mar 23	1,977	-1,996	961	855
31 Dec 22	2,181	-1,951	1,023	937
30 Jun 22	2,595	-144	1,139	992
31 Mar 22	2,817	141	1,134	930
31 Dec 21	3,038	427	1,129	868
30 Sep 21	3,304	681	1,102	815
30 Jun 21	3,317	945	1,049	762
31 Mar 21	2,891	727	954	746
31 Dec 20	2,464	508	859	729
30 Sep 20	2,370	-14	792	698
30 Jun 20	2,275	-537	725	666
31 Mar 20	2,577	-1,623	721	633
31 Dec 19	2,878	-2,709	717	599
30 Sep 19	3,088	-1,927	722	566
30 Jun 19	3,297	-1,144	727	534
31 Mar 19	3,107	238	697	507
31 Dec 18	2,917	1,620	667	480
30 Sep 18	2,751	1,496	580	482
30 Jun 18	2,584	1,372	494	484
31 Mar 18	2,665	1,411	523	394
31 Dec 17	2,746	1,449	553	304
30 Sep 17	2,992	1,632	653	152
30 Jun 17	3,238	1,815	754	0
31 Mar 17	3,212	1,761	720	0
31 Dec 16	3,186	1,708	686	0
30 Sep 16	2,984	1,528	627	0
30 Jun 16	2,781	1,347	568	0
31 Mar 16	2,974	1,705	590	0
31 Dec 15	3,167	2,062	611	0
30 Sep 15	3,321	2,181	648	0
30 Jun 15	3,474	2,299	685	0
31 Mar 15	3,279	1,985	658	0
31 Dec 14	3,084	1,671	630	0
30 Sep 14	2,365	1,581	0	0
30 Jun 14	1,645	1,491	-631	0
31 Mar 14	2,116	1,388	-83	0
31 Dec 13	2,586	1,285	466	0
30 Sep 13	4,355	1,182	2,410	0
30 Jun 13	3,978	1,060	2,163	0

Quality Earnings: TEL1 is currently unprofitable.

Growing Profit Margin: TEL1 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: TEL1 is unprofitable, and losses have increased over the past 5 years at a rate of 11.1% per year.

Accelerating Growth: Unable to compare TEL1's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TEL1 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).

Return on Equity

High ROE: TEL1 has a negative Return on Equity (-5.02%), as it is currently unprofitable.

Sihuan Pharmaceutical Holdings Group Past Earnings Performance

Past criteria checks 0/6

Key information

Recent past performance updates

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

First half 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.004 profit in 1H 2022)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.045 profit in FY 2021)

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.044 profit in FY 2021)

Recent updates

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥0.006 loss per share (vs CN¥0.21 loss in FY 2022)

Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes

Now 21% undervalued

Now 21% undervalued after recent price drop

National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical

First half 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.004 profit in 1H 2022)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Now 22% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval for Clinical Trial

Sihuan Pharmaceutical Holdings Group Ltd. Announces Approval of Phase II Clinical Trial Application of Birociclib by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration

Upcoming dividend of HK$0.037 per share at 9.7% yield

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.045 profit in FY 2021)

Now 24% undervalued after recent price drop

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.044 profit in FY 2021)

Sihuan Pharmaceutical Holdings Group Ltd. Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Less than half of directors are independent

Sihuan Pharmaceutical Holdings Group Ltd. Announces Management Changes

Upcoming dividend of HK$0.037 per share

First half 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.065 in 1H 2021)

Sihuan Pharmaceutical Holdings Group Ltd. Declares Special Cash Dividend for the Six Months Ended 30 June 2022, Payable on or Around 13 October 2022

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2022 Results on Aug 30, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Acceptance of Application for Marketing of Xuanzhu Biopharm\U0027s Drug Fulvestrant Injection by Nmpa of China

Upcoming dividend of HK$0.13 per share

Less than half of directors are independent

Sihuan Pharmaceutical Obtains Class III Medical Device Registration Certificate from NMPA for Exclusively Distributed Hyaluronic Acid Persnica

Now 20% undervalued

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, May 24, 2022

Full year 2021 earnings released: EPS: CN¥0.044 (vs CN¥0.054 in FY 2020)

Sihuan Pharmaceutical Holdings Group Ltd. Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2021, Payable on June 14, 2022

Now 21% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces First Class I Macromolecule Innovative Drug Her2 Bispecific Antibody Xzp-Km257 Was Approves for Clinical Trails

National Medical Products Administration Accepts Biologics License Application of Insulin Aspart Injection, Insulin Aspart 30 Injection and Insulin Aspart 50 Injection of Jilin Huisheng Biopharmaceutical Co., Ltd

Now 22% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces Medical Device Registration Certificate Obtained for Medical Skin Care Gel and Repair Gel

Sihuan Pharmaceutical Holdings Group Ltd. Announces Fondaparinux Sodium Injection Obtained Manufacture Approval

First half 2021 earnings released: EPS CN¥0.065 (vs CN¥0.018 in 1H 2020)

Non-Executive Director Jin-ha Kim has left the company

Upcoming dividend of HK$0.016 per share

Sihuan Pharmaceutical Holdings Group Ltd. Announces Obtains Drug Registration Approval in Relation to Caspofungin Acetate for Injection

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Final Cash Dividend for the Year Ended December 31, 2020, Payable on or Around July 15, 2021

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Two Special Cash Dividends

Full year 2020 earnings released: EPS CN¥0.054 (vs CN¥0.29 loss in FY 2019)

Sihuan Pharmaceutical Holdings Group Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day high: €0.27

Sihuan Pharmaceutical Holdings Group Ltd. Announces Selection of its Pantoprazole Sodium Injection (Panzuoer® 40mg per unit) and Ibuprofen Injection (Falanfen® 4ml: 0.4g, Tenaan® 8ml: 0.8g) in the Fourth Batch of National Drug Centralized Procurement

New 90-day high: €0.25

Sihuan Pharmaceutical Holdings Group Ltd. Announces Cinepazide Maleate Injection Obtain Approval from the National Medical Products Administration

New 90-day high: €0.24

Sihuan Pharmaceutical Holdings Group Ltd.(SEHK:460) dropped from FTSE All-World Index (USD)

First half earnings released

Deputy General Manager recently bought €2.1m worth of stock

First half earnings released

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2020 Results on Aug 25, 2020

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta